Donald Trump signed an executive order directing the FDA to speed up reviews of certain psychedelic drugs already classified as “breakthrough therapies,” especially for treating veterans with serious mental health conditions like PTSD. The order aims to expand research, reduce regulatory delays, and improve access to experimental treatments such as psilocybin and ibogaine.